Kura Oncology KURA Darlifarnib — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's darlifarnib — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's darlifarnib — research and development expense?
- Kura Oncology (KURA) reported darlifarnib — research and development expense of $6.57M in Q1 2026.
- How has Kura Oncology's darlifarnib — research and development expense changed year-over-year?
- Kura Oncology's darlifarnib — research and development expense increased by 25.4% year-over-year, from $5.24M to $6.57M.
- What does darlifarnib — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research, clinical development, and regulatory advancement of the Darlifarnib product candidate. It captures the investment intensity required to progress this specific asset through clinical trials and toward potential commercialization. Monitoring this expense helps investors assess the company's capital allocation strategy and the pace of development for this key pipeline asset.